This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): mAB to TRAIL Receptor 2 - TR2J
Description: HGS-TR2J (TRAIL-R2 mAb) is an agonistic human monoclonal antibody that specifically binds to the TRAIL Receptor-2 protein. TRAIL Receptor 2 often is referred to as a “death receptor” because of its ability to cause apoptosis (programmed cell death) in tumor cells when it is triggered by the natural ligand TRAIL (tumor necrosis factor apoptosis-inducing ligand) . Preclinical studies demonstrate that HGS-TR2J specifically binds TRAIL Receptor 2, induces apoptosis and has anti-tumor activity, both as a single agent and in combination with chemotherapy.
Deal Structure: In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in cash. The acquisition was completed in August 2012.
Pink Sheet Weekly Trademark Review Oct. 28, 2014
Pink Sheet Weekly Trademark Review May 6, 2014
Pink Sheet Weekly Trademark Review Feb. 18, 2014
Additional information available to subscribers only: